In these melanomas, MAPK is activated via CRAF, not BRAF, and these tumors also have aberrant cyclin-dependent kinase (CDK) 4/6 expression and hyperactivated PI3K/AKT signaling. This evidence concerns the gene AKT1 and melanoma.